Tagged as: deal watch

Recent Biosimilars Deals

On January 13, 2021, EVOQ announced a license and collaboration agreement with Amgen for the development of new drugs for autoimmune disorders.  According to the press release, Amgen and EVOQ will collaborate on preclinical development and Amgen will be responsible for clinical development and commercialization.  Amgen’s portfolio includes biosimilars AMGEVITA…

Read More

DEAL WATCH: End-of-Year Biosimilar Agreements

Following the string of biosimilar agreements announced in early November, a number of additional transactions were announced in early December, bringing 2019 to a roaring close with global biosimilars deals. On December 1, 2019, Luye Pharma Group announced that it acquired Shandong Boan Biological Technology Co. Ltd. (Boan), strengthening its…

Read More

DEAL WATCH: Recent Biosimilar Collaboration Announcements

In recent weeks, several drug makers announced collaborations for the development, manufacture, and/or commercialization of a variety of biosimilars or follow-on biologics.  Below are some highlights: On September 3, 2019, Polpharma Biologics and Sandoz announced that they have entered into a global commercialization agreement in connection with Polpharma’s proposed biosimilar…

Read More

Biogen and Samsung BioLogics Close Asset Transfer Deal

As we previously reported, Biogen has exercised its option to purchase additional shares of Samsung Bioepis, increasing Biogen’s ownership in the Samsung Bioepis joint venture from approximately 5.4% to approximately 49.9%.  Last week, Samsung BioLogics announced that the asset transfer deal closed, transferring 9,226,068 shares of Samsung Bioepis to Biogen…

Read More